Hoechst Investment In Asia
By the year 2000, German chemical and pharmaceutical company Hoechst AG will make a fresh investment of $1.8 billion in Asia, according to local reports.
Making the announcement at an industry conference in Singapore, company board member Horst Waesche said that the investment aims at making Hoechst one of the three leading suppliers in its core areas in the region.
Investments in Asia are to be split into three parts: 40% in China, 32% in India, and 28% in the seven member countries of the Association of South East Asian Nations (ASEAN). Asia is expected to represent 20% of Hoechst's global sales by the year 2000, up from 12% at present.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze